A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2011
11/01/2011	US8048852 Antimicrobial compounds and formulations
11/01/2011	US8048850 Anticancer agents
11/01/2011	US8048452 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitor
11/01/2011	US8048438 Apparatus for uniform delivery of drugs to biological systems
11/01/2011	US8048408 addition polymerization of zwitterionic monomers, under molecular weight control, to form polymers having low polydispersity, used for drug delivery
11/01/2011	US8048404 Pharmaceutical composition of nanoparticles for protein drug delivery
11/01/2011	CA2697570C Reduced volume formulation of glatiramer acetate and methods of administration
11/01/2011	CA2617370C Improved cellular uptake of bioactive agents
11/01/2011	CA2605205C Polymeric pharmaceutical agent for treatment of cancer and method for production of the same
11/01/2011	CA2564719C Delivery system for bioactive agents on the basis of a polymeric drug carrier comprising an amphiphilic block polymer and a polylactic acid derivative
11/01/2011	CA2507766C Novel dry powder inhalation system for transpulmonary administration
11/01/2011	CA2497008C Hydroxyalkylstarch-allergen conjugates
11/01/2011	CA2492976C Solution for ungual and peri-ungual application
11/01/2011	CA2490351C Process for producing sustained-release composition
11/01/2011	CA2475224C Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
11/01/2011	CA2453892C Alkyd-lactone copolymers for medical applications
11/01/2011	CA2452056C Compositions of bioactive material particles dispersed in a continuous solid encapsulating material
11/01/2011	CA2443089C Antifungal suspension of micronized posaconazole
11/01/2011	CA2439269C Pharmaceutical salts of 1-phenyl-3-dimethylaminopropane compounds
11/01/2011	CA2434526C Methods of administering epothilone analogs for the treatment of cancer
11/01/2011	CA2431241C Amphiphilic polymers for medical applications
11/01/2011	CA2416097C Modified serum albumin with reduced affinity for nickel and copper
11/01/2011	CA2402247C Biodegradable immunomodulatory formulations and methods for use thereof
11/01/2011	CA2395459C Use of quinoline and quinolizinone derivatives as chemotherapeutic agents
11/01/2011	CA2311318C Mitochondrially targeted antioxidants
11/01/2011	CA2275890C Stable liquid interferon formulations
11/01/2011	CA2203622C Compounds, pharmaceutical composition and diagnostic device comprising them and their use
10/2011
10/27/2011	WO2011133925A2 Targeted and light-activated cytosolic drug delivery
10/27/2011	WO2011133692A1 Boosting immune defense by upregulating ccaat/enhancer binding protein epsilon
10/27/2011	WO2011133675A1 Gabapentin enacarbil compositions
10/27/2011	WO2011133658A1 Compositions and methods for targeting and delivering therapeutics into cells
10/27/2011	WO2011133635A2 Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
10/27/2011	WO2011133566A2 Repairing bruch's membrane with hydrogels
10/27/2011	WO2011133064A1 Method for producing an agent for eliminating skin defects and for treating wounds in the form of a gel based on water-soluble plant-derived polysaccharides
10/27/2011	WO2011133039A2 Novel conjugates of cc-1065 analogs and bifunctional linkers
10/27/2011	WO2011132800A1 Hydrogel
10/27/2011	WO2011132718A1 Composition containing reduced coenzyme q10, and manufacturing and stabilising methods therefor
10/27/2011	WO2011132713A1 Lipid membrane structure with nuclear transferability
10/27/2011	WO2011132018A1 Novel self-assembling peptides and their use in the formation of hydrogels
10/27/2011	WO2011131896A2 Peptide derivatives, preparation thereof and uses thereof as vectors
10/27/2011	WO2011131720A1 New stabilizing agent for pharmaceutical proteins
10/27/2011	WO2011131693A2 Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
10/27/2011	WO2011131671A1 Novel self-assembling peptides and their use in the formation of hydrogels
10/27/2011	WO2011131510A2 Selective modification of proteins
10/27/2011	WO2011131445A1 Active ingredient combinations of magnolia bark extract and polyethoxylated compounds (peg-40 stearates)
10/27/2011	WO2011131441A1 Active ingredient combinations of magnolia bark extract and surface-active agents (polyglyceryl-3 methylglucose distearate)
10/27/2011	WO2011131439A1 Cosmetic or dermatological preparations comprising combinations of magnolia bark extract and alkyl sulphates
10/27/2011	WO2011131370A1 Melt-granulated fingolimod
10/27/2011	WO2011131314A1 Combination of drugs with protein-binding prodrugs
10/27/2011	WO2011130834A1 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof
10/27/2011	WO2011109422A8 Compositions and methods for the treatment of cancer
10/27/2011	WO2011100829A8 Bifunctional chelating agents
10/27/2011	WO2011072103A3 Glycerine based jelly compositions
10/27/2011	WO2011069082A3 Red blood cell-mimetic particles and methods for making and use thereof
10/27/2011	WO2011068894A3 Novel curcumin-antibody conjugates as anti-cancer agents
10/27/2011	WO2011066503A3 Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
10/27/2011	WO2011062420A3 Nanoparticles for tumor-targeting and processes for the preparation thereof
10/27/2011	WO2011060390A3 Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds
10/27/2011	WO2011056653A3 Clonidine formulations having antimicrobial properties
10/27/2011	WO2011039511A3 Agents, uses and methods
10/27/2011	WO2011039510A3 Conjugates targeting the cd163 receptor
10/27/2011	WO2010130396A3 Preparation of acetyl salicylic acid/glutamic acid complex for oral administration
10/27/2011	WO2010119365A3 A medicinal cream made using clotrimazole and chitosan and a process to make the same
10/27/2011	WO2010103374A8 Oily suspension containing probiotic bacteria for paediatric uses
10/27/2011	US20110263724 Threads of hyaluronic acid and/or derivatives, thereof, methods of making thereof and uses thereof
10/27/2011	US20110263722 Well Defined stars with segmented arms
10/27/2011	US20110263683 RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)
10/27/2011	US20110263587 Reversibly heat-gelable aqueous composition
10/27/2011	US20110263568 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
10/27/2011	US20110263481 Pharmaceutical Composition of Lyophilized Formulation and Preparation Method of the Same
10/27/2011	US20110262549 Lipid pellets with enhanced taste-masking
10/27/2011	US20110262542 Controlled Delivery of Tetracycline Compounds and Tetracycline Derivatives
10/27/2011	US20110262527 Cationic lipids and methods of use
10/27/2011	US20110262490 Polymer-agent conjugates, particles, compositions, and related methods of use
10/27/2011	US20110262419 Specifically targeted catalytic antagonists and uses thereof
10/27/2011	US20110262380 Theapeutic use of protein-polymer conjugates
10/27/2011	US20110262379 Maleamic Acid Polymer Derivatives and Their Bioconjugates
10/27/2011	US20110262375 Alkyl-Phenyl Silsesquioxane Resins Compositions
10/27/2011	US20110262366 Compounds for targeting endothelial cells, compositions containing the same and methods for their use
10/27/2011	US20110262347 Methods and compositions for enhanced delivery of compounds
10/27/2011	CA2797098A1 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof
10/27/2011	CA2796729A1 New stabilizing agent for pharmaceutical proteins
10/27/2011	CA2795521A1 A solid pharmaceutical composition for neutralizing stomach acid
10/26/2011	EP2380973A1 Drug made from stem cells with reprogrammed cell signaling, method for producing said preparation and the use thereof
10/26/2011	EP2380657A1 Ceramide dispersion, and process for producing same
10/26/2011	EP2380602A1 Nucleic acids containing plastics in complexed form and method for producing same
10/26/2011	EP2380595A1 Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
10/26/2011	EP2380594A1 Use of serum albumin binding peptides conjugates for the preparation of a medicament
10/26/2011	EP2380593A1 Stabilizing labeled antibody using amino acids
10/26/2011	EP2380579A1 Beneficial effects of increasing local blood flow
10/26/2011	EP2380578A1 Bioactive agent, pharmaceutical product, cosmetic product, freshness keeping agent, and plant and animal growth promoting agent
10/26/2011	EP2380568A1 Method of producing and crystallizing reduced coenzyme Q10
10/26/2011	EP2380563A1 A enteric formulation of duloxetine and its core and prepration method
10/26/2011	EP2380435A2 Feline-derived protein and method for production thereof
10/26/2011	EP2379117A2 Cancer treatment
10/26/2011	EP2379116A2 Antigens associated with endometriosis, psoriatic arthritis and psoriasis
10/26/2011	EP2379115A2 Mono- and di-peg il-10 production; and uses
10/26/2011	EP2379114A1 Conjugates comprising nanoparticles coated with platinum containing compounds
10/26/2011	EP2379113A1 Methods of treating tumor cells using rhcc protein, fragment or variant
10/26/2011	EP2379112A2 Gel adapted for transmitting ultrasound waves, method for making said gel, and bag containing same

1 ... 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 ... 1712